keyword
MENU ▼
Read by QxMD icon Read
search

Chemotherapy hematological

keyword
https://www.readbyqxmd.com/read/29050347/efficacy-and-safety-of-dose-dense-chemotherapy-in-urothelial-carcinoma
#1
Chenjing Zhu, Jiaming Liu, Jing Zhang, Qingfang Li, Qisi Lian, Jing Xu, Xuelei Ma
We conducted a meta-analysis to assess the efficacy and safety of dose-dense chemotherapy in the treatment of patients with urothelial carcinoma. A systematic search was conducted in PubMed, Medline, Embase, Web of Science and Cochrane Collaboration's Central register of controlled trials (CENTRAL) for relevant articles. Data was obtained from 10 trials with a total of 1093 patients. The pooled pathologic complete response (pCR) was 27.8% in the ten studies with a full cohort of 684 patients who received dose-dense methotrexate, vinblastine, adriamycin and cisplatin (dd-MVAC)...
September 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29049199/paclitaxel-as-third-line-chemotherapy-for-small-cell-lung-cancer-failing-both-etoposide-and-camptothecin-based-chemotherapy
#2
Se Hyun Kim, Mi-Jung Kim, Yu Jung Kim, Hyun Chang, Jin Won Kim, Jeong-Ok Lee, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee
Paclitaxel has been shown to have clinical activity in the treatment of small cell lung cancer (SCLC). However, its role as third-line chemotherapy for SCLC after both etoposide- and camptothecin-based regimens has not been clarified.All patients with refractory SCLC who were treated with paclitaxel-based regimen as third-line chemotherapy between 2005 and 2011 in Seoul National University Bundang Hospital were reviewed retrospectively. Forty patients previously treated with both etoposide- and camptothecin-based chemotherapy were included...
October 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29049187/a-myeloid-sarcoma-involving-the-small-intestine-kidneys-mesentery-and-mesenteric-lymph-nodes-a-case-report-and-literature-review
#3
Ping Wang, Quan Li, Li Zhang, Hong Ji, Cheng-Zhou Zhang, Bin Wang
RATIONALE: Myeloid sarcomas (MSs) are rare malignant hematological tumors. They most commonly occur in patients with acute or chronic myeloid leukemia. A de novo MS with no evidence of blood system disease is rare, but may represent the first sign of a systemic illness that precedes a full-blown disease. Herein, we report the computed tomography (CT) findings of an extremely rare case of a nonleukemic MS that progressed to acute myelogenous leukemia (AML) and simultaneously involved the small intestine, kidneys, mesentery, and mesenteric lymph nodes...
October 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29046800/re-irradiation-of-locoregional-esophageal-cancer-recurrence-following-definitive-chemoradiotherapy-a-report-of-6-cases
#4
Atsuto Katano, Hideomi Yamashita, Keiichi Nakagawa
There is currently no consensus on salvage therapy for recurrent esophageal cancer. Salvage surgery is a well-established option for attaining long-term survival; however, it is associated with a high risk of perioperative morbidity and mortality. A total of 6 patients who underwent re-irradiation for recurrence of locoregional esophageal cancer following definitive chemoradiotherapy were investigated. The median interval between initial radiotherapy and re-irradiation was 17.4 months (range, 6.4-59.2 months)...
October 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29045659/bevacizumab-chemotherapy-versus-chemotherapy-alone-in-elderly-patients-with-untreated-metastatic-colorectal-cancer-a-randomized-phase-ii-trial-prodige-20-study-results
#5
T Aparicio, O Bouché, J Taieb, E Maillard, S Kirscher, P-L Etienne, R Faroux, F Akouz Khemissa, F El Hajbi, C Locher, Y Rinaldi, T Lecomte, S Lavau-Denes, M Baconnier, A Oden-Gangloff, D Genet, E Paillaud, F Retornaz, E François, L Bedenne
BACKGROUND: Metastatic colorectal cancer frequently occurs in elderly patients. Bevacizumab in combination with front line chemotherapy is a standard treatment but some concern raised about tolerance of bevacizumab for these patients. The purpose of PRODIGE 20 was to evaluate tolerance and efficacy of bevacizumab according to specific endpoints in this population. PATIENTS AND METHODS: Patients aged 75 and over were randomly assigned to bevacizumab + chemotherapy (BEV) versus chemotherapy (CT)...
September 28, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29044676/world-health-organization-defined-eosinophilic-disorders-2017-update-on-diagnosis-risk-stratification-and-management
#6
Jason Gotlib
DISEASE OVERVIEW: The eosinophilias encompass a broad range of nonhematologic (secondary or reactive) and hematologic (primary, clonal) disorders with potential for end-organ damage. DIAGNOSIS: Hypereosinophilia has generally been defined as a peripheral blood eosinophil count greater than 1500/mm(3) and may be associated with tissue damage. After exclusion of secondary causes of eosinophilia, diagnostic evaluation of primary eosinophilias relies on a combination of morphologic review of the blood and marrow, standard cytogenetics, fluorescent in situ-hybridization, flow immunocytometry, and T-cell clonality assessment to detect histopathologic or clonal evidence for an acute or chronic myeloid or lymphoproliferative disorder...
November 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29042833/impact-of-a-pharmacist-led-chemotherapy-education-program-on-the-knowledge-of-pediatric-hematology-oncology-nurses
#7
Christine M Fisher, Abby J Kim, Joshua J Elder
OBJECTIVES: Medication errors involving chemotherapy are a serious source of avoidable medical harm that can result in chemotherapy-related adverse drug events. Efforts to reduce errors in the past decade have largely focused on chemotherapy errors at the prescriber level, using computerized or automated technology, but little has been done to ensure chemotherapy is administered accurately at the nursing level. The current study implemented a pharmacist-led, supplemental, institution-specific training program to nursing staff regarding the use of chemotherapy and to address knowledge deficits in newly hired nursing personnel...
September 2017: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
https://www.readbyqxmd.com/read/29037236/a-single-arm-phase-ii-study-of-nab-paclitaxel-for-patients-with-chemorefractory-non-small-cell-lung-cancer
#8
Hisashi Tanaka, Kageaki Taima, Takeshi Morimoto, Yoshihito Tanaka, Masamichi Itoga, Kunihiko Nakamura, Akihito Hayashi, Mika Kumagai, Hideo Yasugahira, Megumi Mikuniya, Koichi Okudera, Shingo Takanashi, Sadatomo Tasaka
BACKGROUND: We aimed to evaluate the efficacy and safety of nab-paclitaxel in patients with refractory advanced non-small cell lung cancer who failed previous chemotherapy. METHODS: Patients were required to have an Eastern Cooperative Oncology Group performance status of 0-2 and adequate organ function. Patients received nab-paclitaxel, 100 mg/m(2) i.v. on days 1, 8, and 15 every 4 weeks. The primary endpoint was the overall response rate. Secondary endpoints were the progression-free survival time, overall survival, and the toxicity profile...
October 16, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29037023/simultaneous-integrated-boost-intensity-modulated-radiotherapy-versus-3-dimensional-conformal-radiotherapy-in-preoperative-concurrent-chemoradiotherapy-for-locally-advanced-rectal-cancer
#9
Bong Kyung Bae, Min Kyu Kang, Jae-Chul Kim, Mi Young Kim, Gyu-Seog Choi, Jong Gwang Kim, Byung Woog Kang, Hye Jin Kim, Soo Yeun Park
PURPOSE: To evaluate the feasibility of simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) for preoperative concurrent chemoradiotherapy (PCRT) in locally advanced rectal cancer (LARC), by comparing with 3-dimensional conformal radiotherapy (3D-CRT). MATERIALS AND METHODS: Patients who were treated with PCRT for LARC from 2015 January to 2016 December were retrospectively enrolled. Total doses of 45 Gy to 50.4 Gy with 3D-CRT or SIB-IMRT were administered concomitantly with 5-fluorouracil plus leucovorin or capecitabine...
September 2017: Radiation Oncology Journal
https://www.readbyqxmd.com/read/29035393/donor-lymphocyte-infusion-following-haploidentical-hematopoietic-cell-transplantation-with-peripheral-blood-stem-cell-grafts-and-ptcy
#10
S R Goldsmith, M Slade, J F DiPersio, P Westervelt, M A Schroeder, F Gao, R Romee
Donor-lymphocyte infusion (DLI) for relapse following haploidentical hematopoietic cell transplantation (haploHCT) with post-transplant cyclophosphamide (PTCy) has been described in recipients of bone marrow grafts, but not recipients of G-CSF mobilized peripheral blood (PB) grafts. We retrospectively identified patients who underwent DLI following PB-haploHCT with PTCy for relapse, or loss of chimerism (LOC). Twelve patients (57%) received DLI for hematologic relapse/persistent disease, seven (33%) for extramedullary relapse and two (10%) for LOC...
October 16, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29034435/advances-in-the-treatment-of-paraproteinemic-neuropathy
#11
REVIEW
Eduardo Nobile-Orazio, Mariangela Bianco, Andrea Nozza
Purpose of review Several advances have been made on the pathogenesis and therapy of neuropathies associated with paraproteinemia (monoclonal gammopathy). It is important for the neurologist to understand the pathogenetic relevance of this association especially when the hematological disease does not require per se any therapy. Recent findings Treatment of the neuropathy in patients with malignant paraproteinemia is mainly addressed by the hematologist while the neurologist is mainly involved in the initial diagnosis and in deciding whether the neuropathy is caused by the disease or by the chemotherapy used for the disease...
October 16, 2017: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/29034009/a-multicenter-randomized-study-of-decitabine-as-epigenetic-priming-with-induction-chemotherapy-in-children-with-aml
#12
Lia Gore, Timothy J Triche, Jason E Farrar, Daniel Wai, Christophe Legendre, Gerald C Gooden, Winnie S Liang, John Carpten, David Lee, Frank Alvaro, Margaret E Macy, Carola Arndt, Philip Barnette, Todd Cooper, Laura Martin, Aru Narendran, Jessica Pollard, Soheil Meshinchi, Jessica Boklan, Robert J Arceci, Bodour Salhia
BACKGROUND: Decitabine is a deoxycytidine nucleoside derivative inhibitor of DNA-methyltransferases, which has been studied extensively and is approved for myelodysplastic syndrome in adults but with less focus in children. Accordingly, we conducted a phase 1 multicenter, randomized, open-label study to evaluate decitabine pre-treatment before standard induction therapy in children with newly diagnosed AML to assess safety and tolerability and explore a number of biologic endpoints. RESULTS: Twenty-four patients were fully assessable for all study objectives per protocol (10 in Arm A = epigenetic priming induction, 14 in Arm B = standard induction)...
2017: Clinical Epigenetics
https://www.readbyqxmd.com/read/29033758/resection-of-locally-advanced-pancreatic-neoplasms-after-neoadjuvant-chemotherapy-with-nab-paclitaxel-and-gemcitabine-following-folfirinox-failure
#13
Sarah Hahn, Ahmet Ayav, Anthony Lopez
The incidence of pancreatic cancer has dramatically increased over the past years, but the prognosis has not improved. Between 30 and 40% of tumors are considered locally advanced, essentially due to vascular involvement. In recent years, new chemotherapy protocols with high response rates have been developed. FOLFIRINOX seems to be an interesting option in this situation, but hematologic toxicity could be an obstacle to its prescription. Nab-paclitaxel and gemcitabine offer significant response rates with a reasonable safety profile...
May 2017: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/29032616/a-survey-on-hematology-oncology-pediatric-aieop-centres-the-challenge-of-posterior-reversible-encephalopathy-syndrome
#14
Daniele Zama, Pietro Gasperini, Massimo Berger, Mariagrazia Petris, Maria D De Pasquale, Simone Cesaro, Maria E Guerzoni, Elena Mastrodicasa, Francesca Savina, Ottavio Ziino, Valentina Kiren, Paola Muggeo, Rosa M Mura, Fraia Melchionda, Giulio A Zanazzo
Posterior reversible encephalopathy syndrome (PRES) is one of the most common neurological complications in hematology-oncology pediatric patients. Despite an increasingly recognized occurrence, no clear consensus exists regarding how best to manage the syndrome, because most cases of PRES have reported in single case reports or small series. Aim of this paper is to identify incidence, clinical features, management and outcome of PRES in a large series of hematology-oncology pediatric patients METHODS: The cases of PRES occurred in twelve centres of the Italian Association of Pediatric Haematology and Oncology were reported RESULTS: 124 cases of PRES in 112 pediatric patients were recorded with an incidence of 2...
October 15, 2017: European Journal of Haematology
https://www.readbyqxmd.com/read/29029365/eighteen-month-lamivudine-prophylaxis-on-preventing-occult-hepatitis-b-virus-hbv-infection-reactivation-in-patients-with-hematologic-malignancies-receiving-immunosuppression-therapy
#15
Aldo Marrone, Nicolina Capoluongo, Chiara D'Amore, Mariantonietta Pisaturo, Mariarosaria Esposito, Salvatore Guastafierro, Isabella Siniscalchi, Margherita Macera, Adriana Boemio, Lorenzo Onorato, Luca Rinaldi, Carmine Minichini, Luigi Elio Adinolfi, Evangelista Sagnelli, Lucia Mastrullo, Nicola Coppola
This study evaluated the long-term efficacy and safety of an 18-month lamivudine prophylaxis in 68 HBsAg-negative/anti-HBc-positive patients with onco-hematological disease. All 68 consecutive HBsAg-negative/anti-HBc-positive patients with an onco-hematological disease and naïve for chemotherapy observed from April 2008 to December 2012 at two Hematology Units in Naples were treated with lamivudine for 18 months after stopping chemotherapy and monitored for HBsAg at months 1 and 3 during chemotherapy and then every three months after its discontinuation...
October 13, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29028771/mechanisms-of-thrombocytopenia-during-septic-shock-a-multiplex-cluster-analysis-of-endogenous-sepsis-mediators
#16
Alexandre Bedet, Keyvan Razazi, Florence Boissier, Mathieu Surenaud, Sophie Hue, Stéphane Giraudier, Christian Brun-Buisson, Armand Mekontso Dessap
BACKGROUND: Thrombocytopenia is a common feature of sepsis and may involve various mechanisms often related to the inflammatory response. This study aimed at evaluating factors associated with thrombocytopenia during human septic shock. In particular, we used a multiplex analysis to assess the role of endogenous sepsis mediators. METHODS: Prospective, observational study. Thrombocytopenia was defined as an absolute platelet count <100 G/L or a 50% relative decrease in platelet count during the first week of septic shock...
October 12, 2017: Shock
https://www.readbyqxmd.com/read/29028642/-lost-to-follow-up-among-adult-cancer-survivors
#17
Amitoj Gill, Rohit Gosain, Shruti Bhandari, Rahul Gosain, Gurkirat Gill, Joseph Abraham, Kenneth Miller
BACKGROUND: Follow-up cancer care is important for patients who have received IV chemotherapy but some patients discontinue their care and are lost to follow-up (LFU) at the cancer center where they were treated. The purpose of this study was to determine what proportion of cancer survivors are LFU at 5 years after treatment, the timing of LFU, and the characteristics of those who do not continue survivorship care. METHODS: Adult patients with cancer who were treated with chemotherapy at a large community teaching hospital in 2006 and 2007 were identified and linked with State tumor registry data...
October 12, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29025289/-the-role-of-autologous-hemopoietic-stem-cell-transplantation-in-t-cell-lymphoma-hungarian-data
#18
Árpád Szomor, Renáta Csalódi, Szabolcs Kosztolányi, Ágnes Nagy, Judit Pammer, Orsolya Tóth, Hajna Losonczy, Hussain Alizadeh, Zsófia Miltényi, Péter Reményi, Klára Piukovics
T-cell lymphoma is a poor prognostic hematological malignancy. The generally used - not sufficiently effective - induction chemotherapy should be improved with consolidative autologous hemopoetic stem cell transplantation. The authors describe the role, place and effectiveness of transplantation in this disorder. One hundred thirty three autologous stem cell transplantations were performed in the last 22 years in Hungary. Detailed results are available from the last 6 years. In this period 43 transplantations were carried out in 4 Hungarian centers...
October 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/29025266/the-abcs-of-immunotherapy-for-adult-patients-with-b-cell-acute-lymphoblastic-leukemia
#19
Troy Z Horvat, Amanda N Seddon, Adebayo Ogunniyi, Amber C King, Larry W Buie, Ryan J Daley
OBJECTIVE: To review the pharmacology, efficacy, and safety of Food and Drug Administration approved and promising immunotherapy agents used in the treatment of acute lymphoblastic leukemia (ALL). DATA SOURCES: A literature search was performed of PubMed and MEDLINE databases (1950 to July 2017) and of abstracts from the American Society of Hematology and the American Society of Clinical Oncology. Searches were performed utilizing the following key terms: rituximab, blinatumomab, inotuzumab, ofatumumab, obinutuzumab, Blincyto, Rituxan, Gazyva, Arzerra, CAR T-cell, and chimeric antigen receptor (CAR)...
October 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29023527/dose-escalated-radiotherapy-for-unresectable-or-locally-recurrent-pancreatic-cancer-dose-volume-analysis-toxicity-and-outcome-of-28-consecutive-patients
#20
Sebastian Zschaeck, Bibiana Blümke, Peter Wust, David Kaul, Marcus Bahra, Hanno Riess, Fritz Klein, Marianne Sinn, Uwe Pelzer, Volker Budach, Pirus Ghadjar
PURPOSE: The role of radiotherapy for unresectable pancreatic cancer is controversial. A benefit of additional radiotherapy is supported by some observations. A dose-effect relationship was recently found by dose escalation employing image guided and intensity modulated radiotherapy. METHODS: We retrospectively evaluated 28 consecutive patients, all with history of extensive prior therapies for unresectable locally advanced/ recurrent pancreatic cancer (LAPC/LRPC)...
2017: PloS One
keyword
keyword
69738
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"